39K Stock Overview
Provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Centogene N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.17 |
| 52 Week High | US$1.45 |
| 52 Week Low | US$0.15 |
| Beta | -0.61 |
| 11 Month Change | 0% |
| 3 Month Change | 2.71% |
| 1 Year Change | n/a |
| 33 Year Change | -97.87% |
| 5 Year Change | -98.52% |
| Change since IPO | -98.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 39K | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | -0.02% |
| 1Y | n/a | 17.2% | 8.2% |
Return vs Industry: Insufficient data to determine how 39K performed against the German Healthcare industry.
Return vs Market: Insufficient data to determine how 39K performed against the German Market.
Price Volatility
| 39K volatility | |
|---|---|
| 39K Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine 39K's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 384 | Kim Stratton | www.centogene.com |
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options.
Centogene N.V. Fundamentals Summary
| 39K fundamental statistics | |
|---|---|
| Market cap | €3.06m |
| Earnings (TTM) | -€35.53m |
| Revenue (TTM) | €48.54m |
0.1x
P/S Ratio-0.1x
P/E RatioIs 39K overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 39K income statement (TTM) | |
|---|---|
| Revenue | €48.54m |
| Cost of Revenue | €30.84m |
| Gross Profit | €17.70m |
| Other Expenses | €53.23m |
| Earnings | -€35.53m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.23 |
| Gross Margin | 36.46% |
| Net Profit Margin | -73.21% |
| Debt/Equity Ratio | -260.1% |
How did 39K perform over the long term?
See historical performance and comparison